Standard Curve (Sample)
Infliximab (Remicade) PK ELISA Kit
Infliximab (Remicade) PK
Standard Curve (Sample)
Standard Curve (Sample)
Principle of the Assay: This assay employs the sandwich enzyme immunoassay technique. Anti- Infliximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized anti- Infliximab antibody. After washing away any unbound substances, enzyme linked anti- Infliximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Remicade (domain residing in Fc portion of the Remicade molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples. The color development is stopped and the intensity of the color is measured.
Similar Products
Product Notes
The Infliximab (Remicade) PK (Catalog #AAA13586) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Infliximab (Remicade) PK, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Frequently Asked Questions
What is the pharmacokinetic profile of infliximab (Remicade)?
Infliximab is given through an IV drip, so it quickly enters the bloodstream and spreads to the inflamed area. Infliximab's pharmacokinetic profile involves absorption, distribution, metabolism, and elimination of the drug. It works by blocking TNF-α to reduce inflammation in diseases like rheumatoid arthritis.
What is the half-life of infliximab in humans?
Infliximab stays in the human body for approximately 8 to 9 days. This means half of the drug takes this much time to get eliminated from the body. The half-life can vary depending on individual factors like immune system response.
How is infliximab cleared from the body?
Infliximab gets cleared from the body mainly by being broken down (proteolytic degradation) by the immune system. Cells in the reticuloendothelial system (like in the liver and spleen) chew it up and remove it. Whereas, things like your immune reaction or anti-drug antibodies can speed up or slow this process.
How do anti-drug antibodies affect infliximab pharmacokinetics?
Anti-drug antibodies are like the body's defense squad turning against Infliximab. They hook onto the drug, speeding up its breakdown and removal from the system. This reduces the drug level and makes the treatment less effective. People with a high level of ADA often need a dose adjustment to keep things working.
Does infliximab PK differ between adults and pediatric patients?
Yes, Infliximab's pharmacokinetics do differ a bit between adults and pediatric patients. Children tend to clear the drug faster from their bodies, so it doesn't stick around as long. That's why pediatric doses often need tweaking to keep effective levels and make the treatment work just as well.
How does dosing frequency impact infliximab trough levels?
Increasing the frequency of infliximab dosing can maintain higher trough levels. This means the medication stays effective longer for things like rheumatoid arthritis, without big dips that could let symptoms creep back in.
Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.